Cardioprotective properties of fibrates - Which fibrate, which patients, what mechanism?

被引：41
作者：
Barter, PJ
Rye, KA
机构：
[1] Heart Res Inst, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Heart Res Inst, Sydney, NSW 2006, Australia
[3] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
来源：
CIRCULATION | 2006年 / 113卷 / 12期
关键词：
editorials; cardiovascular diseases; cholesterol; lipoproteins; trials;
D O I：
10.1161/CIRCULATIONAHA.105.620450
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1553 / 1555
页数：3
相关论文
共 14 条
  • [1] [Anonymous], BR MED J
  • [2] Effects of fibrates on serum metabolic parameters
    Elisaf, M
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (05) : 269 - 276
  • [3] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE
    FRICK, MH
    ELO, O
    HAAPA, K
    HEINONEN, OP
    HEINSALMI, P
    HELO, P
    HUTTUNEN, JK
    KAITANIEMI, P
    KOSKINEN, P
    MANNINEN, V
    MAENPAA, H
    MALKONEN, M
    MANTTARI, M
    NOROLA, S
    PASTERNACK, A
    PIKKARAINEN, J
    ROMO, M
    SJOBLOM, T
    NIKKILA, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) : 1237 - 1245
  • [4] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES
    GORDON, DJ
    PROBSTFIELD, JL
    GARRISON, RJ
    NEATON, JD
    CASTELLI, WP
    KNOKE, JD
    JACOBS, DR
    BANGDIWALA, S
    TYROLER, HA
    [J]. CIRCULATION, 1989, 79 (01) : 8 - 15
  • [5] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
    Keech, A
    Simes, RJ
    Barter, P
    Best, J
    Scott, R
    Taskinen, MR
    Forder, P
    Pillai, A
    Davis, T
    Glasziou, P
    Drury, P
    Kesäniemi, YA
    Sullivan, D
    Hunt, D
    Colman, P
    d'Emden, M
    Whiting, M
    Ehnholm, C
    Laakso, M
    [J]. LANCET, 2005, 366 (9500) : 1849 - 1861
  • [6] JOINT EFFECTS OF SERUM TRIGLYCERIDE AND LDL CHOLESTEROL AND HDL CHOLESTEROL CONCENTRATIONS ON CORONARY HEART-DISEASE RISK IN THE HELSINKI HEART-STUDY - IMPLICATIONS FOR TREATMENT
    MANNINEN, V
    TENKANEN, L
    KOSKINEN, P
    HUTTUNEN, JK
    MANTTARI, M
    HEINONEN, OP
    FRICK, MH
    [J]. CIRCULATION, 1992, 85 (01) : 37 - 45
  • [7] Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial
    Otvos, JD
    Collins, D
    Freedman, DS
    Shalaurova, I
    Schaefer, EJ
    McNamara, JR
    Bloomfield, HE
    Robins, SJ
    [J]. CIRCULATION, 2006, 113 (12) : 1556 - 1563
  • [8] Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
    Robins, SJ
    Collins, D
    Wittes, JT
    Papademetriou, V
    Deedwania, PC
    Schaefer, EJ
    McNamara, JR
    Kashyap, ML
    Hershman, JM
    Wexler, LF
    Rubins, HB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (12): : 1585 - 1591
  • [9] Diabetes, plasma insulin, and cardiovascular disease - Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
    Rubins, HB
    Robins, SJ
    Collins, D
    Nelson, DB
    Elam, MB
    Schaefer, EJ
    Faas, FH
    Anderson, JW
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (22) : 2597 - 2604
  • [10] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
    Rubins, HB
    Robins, SJ
    Collins, D
    Fye, CL
    Anderson, JW
    Elam, MB
    Faas, FH
    Linares, E
    Schaefer, EJ
    Schectman, G
    Wilt, TJ
    Wittes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) : 410 - 418
12